Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus

Arch Physiol Biochem. 2022 Oct;128(5):1308-1315. doi: 10.1080/13813455.2020.1768410. Epub 2020 May 23.

Abstract

Background: The MALAT1, MIAT, and XIST long noncoding RNAs (lncRNAs) participate in the pathogenesis of complex diseases and also serve as diagnostic markers. The study aimed to assess their expressions in CAD patients with or without T2DM against diabetic and non-diabetic controls.Methods: The expression levels of three lncRNAs in 50 CAD patients (with or without diabetes) and 50 non-CAD subjects (with or without diabetes) were evaluated by using the TaqMan Assay method.Results: MALAT1 and MIAT were upregulated in CAD patients (p Value= .0008 and .0078, respectively). The expression level of XIST was significantly elevated diabetic compared to non-diabetic CAD patients (p Value= .0003). MALAT1 gene had the highest diagnostic power for discrimination of CAD patients from controls (AUC= 0.682, p Value=.001).Conclusions: The current study supports the participation of lncRNAs in the pathogenesis of CAD and T2DM and highlights their potential as diagnostic biomarkers.

Keywords: Diabetes complications; ROC curve; gene expression; real-time polymerase chain reaction.

MeSH terms

  • Biomarkers
  • Coronary Artery Disease* / complications
  • Coronary Artery Disease* / genetics
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / genetics
  • Diabetes Mellitus, Type 2* / pathology
  • Humans
  • RNA, Long Noncoding* / genetics

Substances

  • Biomarkers
  • MALAT1 long non-coding RNA, human
  • Miat long non-coding RNA
  • RNA, Long Noncoding
  • XIST non-coding RNA